Kevin Webster
Company: Frontier Medicines
Job title: Chief Scientific Officer
Seminars:
Taking a Direct Approach: FMC-376, a Direct Inhibitor of ON+OFF KRAS G12C, Overcomes the Primary Drivers of Both Innate & Acquired Resistance 11:45 am
day: Day One Track B AM
Panel Discussion: Does Pan-RAS Hold the Future of Precision Medicine? Exploring Combination Potential & Targeting Novel Isoforms 9:00 am
What is the current scope and strides in developing pan-RAS inhibitors? What combination therapies should be deployed with pan-RAS and how can we inform this? What is the future of pan-RAS? Will it replace mutant-specific therapies?Read more
day: Day One